title: Involvement of neurotransmitters in urocortin-induced passive avoidance learning in mice.
abstract: The action of urocortin on one-way passive avoidance learning was tested in mice. Urocortin was administered into the lateral brain ventricle and the latency of the passive avoidance response was measured 24 h later. For study of the roles of various neurotransmitters in mediating the action of urocortin on the consolidation of memory, the animals were pretreated with different receptor antagonists. Urocortin facilitated the acquisition, consolidation and also retrieval of the passive avoidance response. The following receptor antagonists blocked the action of urocortin on consolidation: haloperidol, atropine, phenoxybenzamine, bicuculline, the CRF antagonist CRF9-41 and methysergide. Propranolol attenuated, but did not fully block the action of urocortin, while naloxone and nitro-L-arginine were ineffective. The results obtained demonstrate that urocortin is able to improve learning and memory and also retrieval processes in a passive avoidance learning in mice. D2, muscarinic cholinergic, alfa-adrenergic, CRF, serotonergic (5HT 1-2), GABA B receptors are involved in the consolidation of the passive avoidance response.
authors.affiliation: Institute of Pathophysiology, Neurohumoral Research Group of the Hungarian Academy of Sciences, University of Szeged, H-6701 Szeged, Hungary. Telegdy@patph.szote.u-szeged.hu
authors.forename: G
authors.initials: G
authors.lastname: Telegdy
authors.forename: H
authors.initials: H
authors.lastname: Tiricz
authors.forename: A
authors.initials: A
authors.lastname: Adamik
mesh_terms: D000317:Adrenergic alpha-Antagonists / Q000494:pharmacology; D000319:Adrenergic beta-Antagonists / Q000494:pharmacology; D000704:Analysis of Variance; D000818:Animals; D001285:Atropine / Q000494:pharmacology; D001362:Avoidance Learning / Q000187:drug effects* / Q000502:physiology; D001522:Behavior, Animal; D001640:Bicuculline / Q000494:pharmacology; D003346:Corticotropin-Releasing Hormone / Q000494:pharmacology*; D004305:Dose-Response Relationship, Drug; D004338:Drug Combinations; D018756:GABA Antagonists / Q000494:pharmacology; D006727:Hormone Antagonists / Q000494:pharmacology; D008297:Male; D008784:Methysergide / Q000494:pharmacology; D051379:Mice; D018727:Muscarinic Antagonists / Q000494:pharmacology; D018377:Neurotransmitter Agents / Q000378:metabolism*; D010446:Peptide Fragments / Q000494:pharmacology; D010643:Phenoxybenzamine / Q000494:pharmacology; D011433:Propranolol / Q000494:pharmacology; D011930:Reaction Time / Q000187:drug effects; D012702:Serotonin Antagonists / Q000494:pharmacology; D054832:Urocortins
chemical_list: D000317:Adrenergic alpha-Antagonists; D000319:Adrenergic beta-Antagonists; D004338:Drug Combinations; D018756:GABA Antagonists; D006727:Hormone Antagonists; D018727:Muscarinic Antagonists; D018377:Neurotransmitter Agents; D010446:Peptide Fragments; D012702:Serotonin Antagonists; D054832:Urocortins; D010643:Phenoxybenzamine; D001285:Atropine; D003346:Corticotropin-Releasing Hormone; C045089:corticotropin releasing hormone (9-41); D011433:Propranolol; D008784:Methysergide; D001640:Bicuculline